About OncoResponse
OncoResponse is a private company based in Houston, Texas. It has reported $109,039,285 raised in five offerings on Form D since October 2015. Its chief executive is Clifford Stocks.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Apr 21, 2025 | May 6, 2025 | $5,999,138target not set | 9 | $666K | Equity, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| May 1, 2023 | May 12, 2023 | $13,915,153of $40.0M target | 13 | $1.0M | EquityRule 506(b) | Form D ↗ |
| Mar 17, 2021 | Mar 31, 2021 | $40,625,995of $60.0M target | 14 | $2.9M | EquityRule 506(b) | Form D ↗ |
| Aug 23, 2018 | Sep 6, 2018 | $18,999,999of $39.9M target | 12 | $1.5M | EquityRule 506(b) | Form D ↗ |
| Sep 30, 2015 | Oct 15, 2015amended Mar 23, 2017 | $29,499,000of $34.0M target | 12 | $2.4M | EquityRule 506(b) | Form D/A ↗2 earlier filings |
| Total, five offerings | $109,039,285 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on OncoResponse's Form D filed May 6, 2025.
Earlier filings also listed Ted Koutouzis (director, last listed May 2023), Bob Lechleider (executive officer, last listed May 2023), Patrick Hojlo (director, last listed Mar 2021), Daguang Wang (director, last listed Mar 2021), Nathan Jorgensen (director, last listed Sep 2018), Andrew Perlman (director, last listed Sep 2018), Russ Hawkinson (chief financial officer, last listed Mar 2017) and Alan Ginsberg (director, last listed Mar 2017).